

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2018

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for current period ended	Figures for previous period ended
		31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	34.08	0.00	5.74	229.80	30.62
II	Other Income	0.00	0.00	0.25	15.98	0.25
III	Total Income (I + II)	34.08	0.00	5.99	245.78	30.87
IV	Expenses:					
	Cost of Materials Consumed	0.17	0.00	0.00	101.70	0.00
	Purchases of Stock in Trade	0.00	0.00	0.00	86.94	12.13
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	4.50	5.06	0.70	12.96	2.00
	Finance Costs	0.00	0.00	0.01	0.00	0.01
	Depreciation & amortisation expense	0.01	0.01	0.01	0.04	0.03
	Other Expenses	15.92	4.06	4.42	31.69	13.31
	Total Expenses (IV)	20.60	9.13	5.14	233.33	27.48
V	Profit / (loss) before exceptional items and tax (III-IV)	13.48	-9.13	0.85	12.45	3.39
VI	Exceptional Items	-28.82	0.00	0.00	-28.82	0.00
VII	Profit / (loss) before tax (V-VI)	-15.34	-9.13	0.85	-16.37	3.39
VIII	Tax Expense:					
	(1) Current tax	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-15.34	-9.13	0.85	-16.37	3.39
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-15.34	-9.13	0.85	-16.37	3.39
XIV	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss					
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-15.34	-9.13	0.85	-16.37	3.39
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	0.00	0.00	0.02	0.00	0.06
	(2) Diluted	0.00	0.00	0.02	0.00	0.06
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic					
	(2) Diluted	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):					
	(1) Basic	0.00	0.00	0.02	0.00	0.06
	(2) Diluted	0.00	0.00	0.02	0.00	0.06
	NOTES:					
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.					
2	The Segment - wise details are not applicable to the Company as the Company has no segments.					
3	The results are Ind-AS compliant however, the previous year figures are not subject to limited review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.					
4	Loss during the quarter is due to write off of receivables and payables					
5	Previous period's figures have been reclassified / regrouped, wherever necessary.					

For Rubra Medicaments Limited

Place: Mumbai
Date:- May 28, 2018

Abha Kapoor
Director (Finance) & CFO
DIN: 02799429

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

	Particulars	Figures as at the end of current reporting period		Figures as at the end of the previous reporting period	
		March 31, 2018		March 31, 2017	
		Audited		Audited	
	ASSETS				
1	Non-current assets				
	(a) Property, plant and equipment	0.05		0.08	
	(b) Capital work-in-progress	-		-	
	(c) Investment property	-		-	
	(d) Goodwill	-		-	
	(e) Other intangible assets	-		-	
	(f) Intangible assets under development	-		-	
	(g) Biological assets other than bearer plants	-		-	
	(h) Financial Assets				
	(i) Investments	-		-	
	(ii) Trade receivables	-		-	
	(iii) Loans	-		-	
	(iv) Others (to be specified) - Advances	-		33.79	
	(i) Deferred tax assets (net)	-		-	
	(j) Other non-current assets	1.77		1.69	
	Total non-current assets	1.82		35.56	
2	Current assets				
	(a) Inventories	-		-	
	(b) Financial Assets				
	(i) Investments	-		-	
	(ii) Trade receivables	34.37		1.77	
	(iii) Cash and cash equivalents	29.74		15.55	
	(iv) Bank balances other than (iii) above	3.89		-	
	(v) Loans	11.50		-	
	(vi) Others to be specified	-		-	
	(c) Current tax assets (net)	-		-	
	(d) Other current assets	-		-	
	Total current assets	79.50		17.32	
	Total assets	81.32		52.88	
1	EQUITY AND LIABILITIES				
	Equity				
	(a) Equity share capital	546.83		546.83	
	(b) Other equity	-487.64		-505.03	
	Total equity	59.19		41.80	
	LIABILITIES				
2	Non-current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	-		-	
	(ii) Trade payables	-		-	
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-		-	
	(b) Provisions	-		-	
	(c) Deferred tax liabilities (net)	0.01		7.47	
	(d) Other non-current liabilities	-		-	
	Total non-current liabilities	0.01		7.47	
	Current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	-		-	
	(ii) Trade payables	16.57		3.32	
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-		-	
	(b) Other current liabilities	-		-	
	(c) Provisions, current	5.55		0.29	
	(d) Current tax liabilities (Net)	-		-	
	Total current liabilities	22.12		3.61	
	Total liabilities	22.13		11.08	
	Total Equity and Liabilities	81.32		52.88	